- Home
- VATE vs ZNTL Comparison
VATE vs ZNTL Comparison
Compare VATE & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VATE
- ZNTL
- Stock Information
- Founded
- VATE 1994
- ZNTL 2014
- Country
- VATE United States
- ZNTL United States
- Employees
- VATE N/A
- ZNTL N/A
- Industry
- VATE Metal Fabrications
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- VATE Industrials
- ZNTL Health Care
- Exchange
- VATE Nasdaq
- ZNTL Nasdaq
- Market Cap
- VATE 98.2M
- ZNTL 105.8M
- IPO Year
- VATE 1996
- ZNTL 2020
- Fundamental
- Price
- VATE $5.26
- ZNTL $1.32
- Analyst Decision
- VATE
- ZNTL Buy
- Analyst Count
- VATE 0
- ZNTL 7
- Target Price
- VATE N/A
- ZNTL $8.60
- AVG Volume (30 Days)
- VATE 44.2K
- ZNTL 961.9K
- Earning Date
- VATE 08-06-2025
- ZNTL 08-08-2025
- Dividend Yield
- VATE N/A
- ZNTL N/A
- EPS Growth
- VATE N/A
- ZNTL N/A
- EPS
- VATE N/A
- ZNTL N/A
- Revenue
- VATE $1,066,100,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- VATE N/A
- ZNTL N/A
- Revenue Next Year
- VATE N/A
- ZNTL N/A
- P/E Ratio
- VATE N/A
- ZNTL N/A
- Revenue Growth
- VATE N/A
- ZNTL N/A
- 52 Week Low
- VATE $3.25
- ZNTL $1.01
- 52 Week High
- VATE $13.79
- ZNTL $5.70
- Technical
- Relative Strength Index (RSI)
- VATE 39.84
- ZNTL 47.15
- Support Level
- VATE $5.17
- ZNTL $1.31
- Resistance Level
- VATE $5.55
- ZNTL $1.54
- Average True Range (ATR)
- VATE 0.28
- ZNTL 0.14
- MACD
- VATE -0.03
- ZNTL -0.00
- Stochastic Oscillator
- VATE 13.43
- ZNTL 31.36
About VATE INNOVATE Corp.
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.